Meet Healthfundr: Equity-Based Crowdfunding For Health Startups
When Marshall McLuhan said that the medium is the message in the 1960s, it’s amazing to think about how much that idea still applies in present culture. What he meant is that new forms of media (technology) transform our experience and is ultimately more important than the content that is shared. In other words, technology [...]... Read More
Archive for the ‘BioScience’ Category
RECENT:
-
Danforth Plant Science Center To Continue Investment In Robotics in 2013
BY: Kathryn HoughJim Carrington, the president of the Danforth Plant Science Center in St. Louis, confirmed today that the center will continue to invest in lab procedure automation robots.
read more -
Monsanto Ups Its Venture Capital Game To Grow Product Pipeline
BY: Kathryn HoughSt. Louis-based Monsanto aims to get a sneak peek at emerging agricultural technologies by boosting the company’s venture capital arm in 2013. The company signaled its investment-focused ramp up by hiring venture capitalist John Hamer in September who joined the company as investment director of Monsanto Growth Ventures.
read more -
SLU Researchers Land $1.8 Million For Lupus Research
BY: Kathryn HoughResearchers in Saint Louis University’s division of rheumatology in the department of internal medicine will be one step closer to understanding the disease lupus thanks to a $1.8 million grant from the National Institute of Health.
read more -
St. Louis’ CORTEX Begins Phase II With $186M Investment
BY: Corey CummingsThis week CORTEX, a growing technology district in St. Louis, has unveiled Phase II of its 20 year plan to become one of the largest tech hubs in the Midwest.
read more -
Kypha Raises $1.5M To Bring Compact Health Diagnosis Tech To Market
BY: Corey CummingsSt. Louis-based medtech company Kypha has raised nearly $2.5 million over the past year to bring its premier technology, the CompAct test, to the market in 2013.
read more -
Confluence Raises $4M To Accelerate Novel Cancer Treatment Research
BY: Corey CummingsConfluence, a St. Louis-based biomedical research company, announced that it has secured $4 million in series A venture capital financing this week that will help further the company’s research of kinase inhibitor cancer treatments.
read more
Is St. Louis The Next Big Game Development City? 
International Spotlight: The Tech Startup Scene In Perth, Australia
Using Twitter To Help Oklahoma Tornado Victims